Compounding pharmacies eager to cash in on the peptide boom are watching closely as the nation’s top health official pushes to legalize the market. A regulatory minefield may mean a long wait.
AI-focused biotech Profluent said Tuesday it has entered a multiprogram, strategic research collaboration with Eli Lilly and Co. to treat diseases with high unmet need, in a deal that involves an upfront payment and up to $2.25 billion in additional milestone payments.
Experts told Law360 that Health and Human Services Secretary Robert F. Kennedy Jr. appears to be avoiding “politically unsavory” issues and focusing on more popular health policies across his hearings this week. Here, Law360 looks at experts' three takeways.